Sobi Canada Inc.

13 articles about Sobi Canada Inc.

• Annals of Rheumatic Diseases Publishes Results from Phase 2 Study of emapalumab in Patients with Secondary HLH/Macrophage Activation Syndrome

  4/4/2023

  Sobi North America announced that the Annals of Rheumatic Diseases has published results from an open-label, single-arm, multicenter phase 2 study evaluating the safety and efficacy of emapalumab, an anti-interferon-gamma monoclonal antibody, being investigated in patients with sJIA or AOSD who developed sHLH/Macrophage Activation Syndrome following an inadequate response to high-dose glucocorticosteroids.

• 

  Clinical Catch-Up for July 8-12

  7/15/2019

  It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look.
• 

  Extended Half-Life Prophylaxis Improves Quality of Life in Hemophilia Patients, Study Shows

  7/9/2019

  The introduction of EHLs allowed hemophilia patients to live a life beyond their disease, with improved quality of life, the study showed.

• Sobi Presents Study Data Supporting Increased Possibilities and Improved Clinical Outcomes for People With Haemophilia at ISTH

  6/25/2019

  It will be the first time interim results from the global, prospective verITI-8 study of rFVIIIFc for first-time ITI will be presented.

• Sobi Presents Update on State of Newborn Screening for HT-1 in the United States at APHL 2019 Newborn Screening and Genetic Testing Symposium

  4/8/2019

  Newborn screening is essential to rapid diagnosis of HT-1

• Sobi to Showcase Latest Rare Disease and Specialty Care Research at Multiple Spring 2019 Scientific Meetings

  4/4/2019

  Sobi announced that investigators will present data from across its rare disease and specialty care portfolio at multiple scientific meetings this Spring.

• Sobi and Novimmune Selected as Honourees for 2019 National Organization for Rare Disorders (NORD) Rare Impact Award in Industry Innovation for Gamifant® (emapalumab)

  3/25/2019

  Sobi™ and Novimmune SA have both been selected as honourees by the National Organization for Rare Disorders for the 2019 Rare Impact Awards.

• FDA Approves Gamifant® (emapalumab-lzsg), the First and Only Treatment Indicated for Primary Hemophagocytic Lymphohistiocytosis (HLH)

  11/20/2018

  Primary HLH is an ultra-rare syndrome of hyper-inflammation that usually occurs within the first year of life and can rapidly become lethal unless diagnosed and treated

• 

  Biotech Movers and Shakers Aug. 27

  8/27/2018

  Who made a splash in the biotech world this week? Here are some notable people.

• Sobi Names Jeff Henderson Vice President, Head of Market Access and Government Affairs, U.S.

  8/1/2018

  Henderson will build the Sobi patient access team in the U.S.

• Sobi Receives Approval from Health Canada for Once-Daily Dosing of Orfadin® (nitisinone) for the Treatment of HT-1

  4/17/2018

  - First and only nitisinone product in Canada approved for once-daily use, designed to meet the needs of HT-1 patients entering older childhood, adolescence and adulthood -

• Sobi’s Orfadin® (nitisinone) Receives Positive Reimbursement Recommendation for the Treatment of HT-1 from CADTH Canadian Drug Expert Committee

  2/27/2018

  Sobi intends to continue taking the necessary steps to ensure Orfadin remains accessible to Canadian patients.

• Sobi Canada Release: Health Canada Approves Orfadin Capsules For Treatment Of Hereditary Tyrosinaemia Type-1 (HT-1)

  1/4/2017